Clicky

Shionogi & Co Ltd(SGIOF)

Description: Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. The company primarily focuses on metabolic syndrome, pain, infectious diseases, cholesterol medication, anti-hypertension drugs, depression treatment, prescription drugs, OTC drugs, and diagnostics. Its primary products include Cymbalta, a serotonin and noradrenaline reuptake inhibitor used for the treatment of depression, anxiety, diabetic neuropathic pain, fibromyalgia pain, chronic lower back pain, and osteoarthritis pain; Intuniv, a selective a2 adrenergic receptor agonist to treat attention-deficit hyperactivity disorder; Xofluza, an anti-influenza agent; and Symproic, a cancer pain analgesic tablet. It has a research collaborative agreement with National University Corporation Kyoto University to focus on drug discovery and medical research for the treatment of psychiatric disorders; strategic collaboration with Sage Therapeutics, Inc. to develop and commercialize SAGE-217 for MDD and other indications; license and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics Inc.; a strategic collaboration with Tetra Discovery Partners LLC for the clinical development and commercialization of BPN14770, a selective phosphodiesterase-4D allosteric inhibitor; and a collaborative research agreement with PeptiDream Inc. for the discovery and development of a series of blood brain barrier penetrating peptide drug-conjugates. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.


Keywords: Cancer Drugs Pain Infectious Diseases Chemical Compounds Drug Discovery Hypertension Arthritis Influenza Osteoarthritis Depression Medical Research Cholesterol Analgesic Neuropathic Pain Fibromyalgia Attention Deficit Hyperactivity Disorder Sterol Anxiety Back Pain Treatment Of Depression Psychiatric Disorders Hyperactivity Disorder A2 Attention Shionogi Kyoto University Metabolic Syndrome N1 Deficit Duloxetine Treatment Of Psychiatric Disorders Depression Treatment Mycobacterial Diseases Naldemedine National University Corporation Kyoto University Symproic Treatment Of Mycobacterial Diseases

Home Page: www.shionogi.com

1-8, Doshomachi 3-chome
Osaka, 541-0045
Japan
Phone: 81 6 6202 2161


Officers

Name Title
Dr. Isao Teshirogi Ph.D. Chairman, CEO & Pres
Susumu Mitsumori VP of Fin. & Accounting Department
Mr. Kazuhiro Hatanaka Sr. Exec. Officer & Sr. VP of Admin. Division
Mr. Takeshi Shiota Ph.D. Corp. Officer and Sr. VP of Corp. Quality Assurance, Ethics & Compliance Management Div.
Mr. Yoshimasa Kyokawa VP of Corp. Communications & Sec. Office
Yoshihiro Furuya VP of Gen. Marketing and Compliance Officer of Corp. GXP Compliance Office
Mr. Kohji Hanasaki Ph.D. Sr. Exec. Officer and Sr. VP of Supply Supervisory Unit & Global Bus. Division
Dr. John A. Keller Ph.D. Sr. Exec. Officer and Sr. VP of R&D Supervisory Unit
Akira Kato Ph.D. Corp. Officer & Pres of Shionogi Pharma Co., Ltd
Dr. Ryuichi Kiyama Ph.D. Sr. Exec. Officer & Sr. VP of Corp. Strategy Division

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 15.4799
Trailing PE: 15.9596
Price-to-Book MRQ: 2.0122
Price-to-Sales TTM: 0.0442
IPO Date:
Fiscal Year End: March
Full Time Employees: 5693
Back to stocks